Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxcarbazepine is an anticonvulsant medication primarily used to treat epilepsy, specifically for the control of partial (focal) seizures in adults and children. It can be used alone or in combination with other antiepileptic drugs. Oxcarbazepine acts as a prodrug and is metabolized to its active form, licarbazepine (10-monohydroxy derivative). The drug works mainly by blocking voltage-sensitive sodium channels in neuronal membranes, stabilizing hyper-excited neural membranes, suppressing repetitive neuronal firing, and reducing synaptic impulse propagation. Additional effects may include enhanced potassium conductance and modulation of high-voltage activated calcium channels. Oxcarbazepine was developed as a safer alternative to carbamazepine with reduced hepatic risks due to differences in metabolism[1][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxcarbazepine.